St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00451516|
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : May 19, 2008
SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety commonly occurs, it is conceivable that a combination of an established antidepressant agent such as SJW and an established anxiolytic agent such as kava may effectively treat MDD presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid anxiety, than by the individual substances alone. Determination of this is not addressed in this study due to limitations of time and resources. The determination of the strength of the SJW-kava combination will be ascertained by comparing similar trials using SJW and kava mono-therapy in addressing MDD and GAD.
The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo.
|Condition or disease||Intervention/treatment||Phase|
|Depressive Disorder, Major Anxiety Disorders||Drug: Herbal medicine (St. John's wort and Kava)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
- BDI II
- Daily Mood Monitoring Form
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451516
|Brisbane, Queensland, Australia, 4006|
|Principal Investigator:||Jerome Sarris, BHSc||The University of Queensland|